Free Trial
NASDAQ:ACTU

Actuate Therapeutics (ACTU) Stock Price, News & Analysis

Actuate Therapeutics logo
$8.94 -0.06 (-0.67%)
(As of 11/22/2024 ET)

About Actuate Therapeutics Stock (NASDAQ:ACTU)

Key Stats

Today's Range
$8.75
$9.00
50-Day Range
$5.80
$9.23
52-Week Range
$5.51
$10.16
Volume
31,446 shs
Average Volume
45,514 shs
Market Capitalization
$174.60 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of cancers. The company's lead product candidate is Elraglusib Injection, a novel glycogen synthase kinase-3 inhibitor to treat metastatic pancreatic ductal adenocarcinoma. It also develops Elraglusib for the treatment of Ewing sarcoma, metastatic melanoma, and colorectal cancer. The company was formerly known as Apotheca Therapeutics, Inc. and changed its name to Actuate Therapeutics, Inc. in October 2015. The company was incorporated in 2015 and is based in Fort Worth, Texas.

Receive ACTU Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Actuate Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ACTU Stock News Headlines

Trump Wins… But Elon Says Get Ready to Brace
Trump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy with a heavy hand—building up infrastructure, slapping tariffs on imports, and going all-in on U.S. jobs. But here's the kicker: while Trump's focused on making America stronger, the Washington elite is ready to fight back…
Actuate Therapeutics Inc ACTU
See More Headlines

ACTU Stock Analysis - Frequently Asked Questions

Actuate Therapeutics' stock was trading at $8.61 at the beginning of 2024. Since then, ACTU stock has increased by 3.8% and is now trading at $8.94.
View the best growth stocks for 2024 here
.

Actuate Therapeutics (NASDAQ:ACTU) posted its earnings results on Tuesday, September, 24th. The company reported ($4.20) earnings per share for the quarter.

Actuate Therapeutics (ACTU) raised $27 million in an initial public offering on Tuesday, August 13th 2024. The company issued 3,000,000 shares at a price of $8.00-$10.00 per share. Titan Partners acted as the underwriter for the IPO and Newbridge Securities Corp. was co-manager.

Top institutional investors of Actuate Therapeutics include Northwestern University (0.14%) and KG&L Capital Management LLC (0.06%). Insiders that own company stock include Equity Cof Lp Bios, Todd S Thomson and Leslie W Kreis.
View institutional ownership trends
.

Shares of ACTU stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Actuate Therapeutics investors own include Arch Capital Group (ACGL), Adobe (ADBE), Analog Devices (ADI), Alnylam Pharmaceuticals (ALNY), Aileron Therapeutics (ALRN), Amgen (AMGN) and AstraZeneca (AZN).

Company Calendar

Last Earnings
9/24/2024
Today
11/22/2024
Next Earnings (Estimated)
12/24/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:ACTU
Previous Symbol
NASDAQ:ACTU
Web
N/A
Fax
N/A
Employees
10
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$0.27 per share

Miscellaneous

Free Float
N/A
Market Cap
$174.60 million
Optionable
N/A
Beta
N/A
Beginners Guide To Retirement Stocks Cover

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

This page (NASDAQ:ACTU) was last updated on 11/23/2024 by MarketBeat.com Staff
From Our Partners